| Date | Title | Description |
| 25.06.2024 | iOnctura's Precision Cancer Treatments Gain Momentum | iOnctura, a clinical-stage biopharmaceutical company based in Amsterdam, recently secured EUR80 million in Series B financing to accelerate the development of their lead asset, roginolisib, for the treatment of uveal melanoma and other onco... |
| 24.06.2024 | iOnctura closes EUR80 million Series B financing |
iOnctura, a clinical-stage biopharmaceutical company combating neglected and hard-to-treat cancers, today announces that it has closed an EUR80 million Series B financing. The funding round was led by new investor Syncona Limited with part... |
| 20.06.2024 | iOnctura Raises EUR80M in Series B Financing | iOnctura, an Amsterdam, the Netherlands-based clinical-stage biopharmaceutical company, raised EUR80M in Series B funding.
The round was led by Syncona, with participation from the European Innovation Council Fund as well as existing invest... |
| 20.03.2024 | FDA approvals and encouraging results for innovative therapies |
Idorsia announced today that the US Food and Drug Administration (FDA) has approved TRYVIO (aprocitentan) for the treatment of hypertension in combination with other antihypertensive drugs, to lower blood pressure in adult patients who are... |
| 20.10.2023 | Early-stage pharmaceutical companies make strides in cancer- and immunotherapy | |
| 30.03.2023 | US and UK authorities give Swiss biotechs green light to accelerate cancer therapies | |
| 21.12.2022 | iOnctura Receives €17.5M Funding from the EIC Accelerator | iOnctura BV, an Amsterdam, Netherlands-based clinical-stage biotech developing cancer therapies, raised €17.5M in funding.
EIC Accelerator provided the financing, which consisted of:
a grant of EUR2.5M, and
EUR15M of equity investment.
The ... |
| 22.09.2022 | FIF funding supports three women led deeptech startups | The FIF is the instrument for fostering innovation and the scale up of promising companies from the Canton of Geneva at the service of the United Nations (UN) Sustainable Development Goals (SDGs). The FIF is supported by the State of Geneva... |
| 08.04.2022 | iOnctura Presents Data at AACR Demonstrating its Unique Mechanism of Action for Clinical Stage ATX Inhibitor IOA-289 | GENEVA, Switzerland, April 08, 2022 (GLOBE NEWSWIRE) -- iOnctura SA, a clinical-stage oncology company targeting core resistance and relapse mechanisms at the tumor-stroma-immune interface, has preclinical data that shows its autotaxin inhi... |
| 09.12.2021 | iOnctura Shows No Dose-limiting Toxicity and Reduced T-regs in Solid Tumor Study of PI3Kδ Inhibitor IOA-244 Presented at ESMO-IO | GENEVA, Switzerland, Dec. 09, 2021 (GLOBE NEWSWIRE) -- iOnctura SA, a clinical stage oncology company targeting core resistance and relapse mechanisms at the tumor-stroma-immune interface, is presenting clinical data on its lead pipeline as... |
| 09.12.2021 | iOnctura Presents Positive Clinical Data At ESMO-IO Supporting Advancement of IOA-289, a Novel Autotaxin Inhibitor, Into Phase Ib Pancreatic Cancer Studies | GENEVA, Switzerland, Dec. 09, 2021 (GLOBE NEWSWIRE) -- iOnctura SA, a clinical stage oncology company targeting core resistance and relapse mechanisms at the tumor-stroma-immune interface, is presenting clinical data confirming the mode of ... |
| 23.11.2021 | iOnctura to Share Clinical and Preclinical Data on IOA-244 and IOA-289 at ESMO-IO in December | GENEVA, Nov. 23, 2021 (GLOBE NEWSWIRE) -- iOnctura SA, a clinical stage oncology company targeting core resistance and relapse mechanisms at the tumor-stroma-immune interface, announces it will present clinical and preclinical data on two p... |
| 23.11.2021 | iOnctura to Share Clinical and Preclinical Data on IOA-244 and IOA-289 at ESMO-IO in December | GENEVA, Nov. 23, 2021 (GLOBE NEWSWIRE) -- iOnctura SA, a clinical stage oncology company targeting core resistance and relapse mechanisms at the tumor-stroma-immune interface, announces it will present clinical and preclinical data on two p... |
| 12.11.2021 | iOnctura Presents Compelling Preclinical Data on its Clinical Stage Autotaxin Inhibitor IOA-289 at SITC | GENEVA, Switzerland, Nov. 12, 2021 (GLOBE NEWSWIRE) -- iOnctura SA, a clinical stage oncology company targeting core resistance and relapse mechanisms at the tumor-stroma-immune interface, presented compelling preclinical evidence on its ne... |
| 08.11.2021 | iOnctura Clinical Expansion Positions Lead PI3Kδ Inhibitor IOA-244 for Potential Registration Studies in Metastatic Uveal Melanoma | Expansion of DIONE-01 supports subsequent transition to registration studies in metastatic uveal melanoma
DIONE-01 trial design expanded with multiple cohorts including solid and hematologic malignancies
DIONE-01 Part A data to be presented... |
| 08.11.2021 | iOnctura Clinical Expansion Positions Lead PI3Kδ Inhibitor IOA-244 for Potential Registration Studies in Metastatic Uveal Melanoma | Expansion of DIONE-01 supports subsequent transition to registration studies in metastatic uveal melanoma
DIONE-01 trial design expanded with multiple cohorts including solid and hematologic malignancies
DIONE-01 Part A data to be presented... |
| 02.11.2021 | iOnctura to Share Preclinical Data on IOA-289 at SITC in November | GENEVA, Nov. 02, 2021 (GLOBE NEWSWIRE) -- iOnctura SA, a clinical stage oncology company targeting core resistance and relapse mechanisms at the tumor-stroma-immune interface, announces that it will present preclinical data on its next gene... |
| 02.11.2021 | iOnctura to Share Preclinical Data on IOA-289 at SITC in November | GENEVA, Nov. 02, 2021 (GLOBE NEWSWIRE) -- iOnctura SA, a clinical stage oncology company targeting core resistance and relapse mechanisms at the tumor-stroma-immune interface, announces that it will present preclinical data on its next gene... |
| 12.08.2021 | New executives take their seat | For its Asian operations, Zug-based cryptobank Seba has named former Credit Suisse and Barclays investment banker Sam Lin as CEO Asia. With over 15 years of experience in investment banking at Credit Suisse and Barclays, Sam is a highly exp... |
| 06.08.2021 | Startups ink new partnerships | Scantrust has entered into a global agreement with ePAC to provide its scanning technology to develop a new connected packaging and connected goods service. Under the name ePacConnect, the service uses Scantrust serialized and secured QR co... |
| 15.07.2020 | With €20.1M funding, Swiss biotech startup iOnctura aims to treat cancer and fibrosis effectively | Cancer is one of the most deadly diseases and is estimated to affect one in three people, especially in the western world. WHO (World Health Organisation) claims that there has been a 70% increase in the number of cancer cases across the wo... |
| 14.07.2020 | iOnctura extends series A round to €20 million | iOnctura SA is a clinical-stage biopharmaceutical company developing a pipeline of next-generation molecules targeting cancer and fibrosis. The company’s lead programme, IOA-244, entered the clinic in Q1 2020 to clinically demonstrate for t... |
| 14.07.2020 | 3B Future Health Fund Announces New Investment in iOnctura | MONACO, PRINCIPALITY OF MONACO, 14 July 2020: 3B Future Health Fund, previously known as Helsinn Investment Fund S.A., SICAR, today announces that it has invested in iOnctura SA, a clinical stage biopharmaceutical company developing a pipel... |
| 14.07.2020 | iOnctura Raises Additional €5.1M; Series A to €20.1M | iOnctura SA, a Geneva, Switzerland-based clinical stage biopharmaceutical company developing a pipeline of next generation molecules targeting cancer and fibrosis, raised an additional €5.1m in Series A financing to €20.1m.
New investor 3B ... |
| 14.07.2020 | iOnctura extends series A round to €20 million | |
| 27.02.2020 | iOnctura announces start of clinical trial | The dose escalation part of the study will evaluate the safety, tolerability and pharmacokinetic profile of IOA-244 and is being led by principal investigators Professor Evans from the Beatson West of Scotland Cancer Centre and University o... |
| 27.02.2020 | iOnctura announces start of clinical trial | |
| 24.01.2020 | iOnctura Raises €15M in Series A Financing | iOnctura B.V., a Geneva, Switzerland-based clinical stage biopharmaceutical company developing a pipeline of molecules targeting cancer and fibrosis, closed a €15m Series A financing.
The round was led by INKEF Capital and co-led by VI Part... |
| 24.01.2020 | Geneva-based biopharma startup raises €15 million | |
| 24.01.2020 | Geneva-based biopharma startup raises €15 million | iOnctura is a clinical-stage biopharmaceutical company founded as a spin-out from Merck, with Merck and Cancer Research UK. The company provides a best-in-class pipeline of molecules that harness both direct and immune-mediated anti-cancer ... |
| - | iOnctura | “iOnctura is a clinical stage biopharmaceutical company dedicated to delivering innovative cancer treatments to patients with unmet medical need. Company developing molecules that individually harness the combined effect of immune-mediated ... |
